에 대한 최신 뉴스 Ascendis Pharma (NASDAQ:ASND) 주식

Ascendis Pharma

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Mid Cap

News

Movers

Trading Ideas

ASND

BLCO

EWTX

NUVL

POWL

지난주 연방준비제도(연준)가 금리를 50bp(베이시스 포인트) 인하하기로 결정하면서 기술, 건설, 산업, 기계 그리고 금융 부문 전반에 걸쳐 주가가 상승했다. 지난주 가장 좋은 실적을 보인 중형주 7종목은 다음과 같다. 여러분의 포트폴리오에 포함되어 있나요?

바우쉬 헬스와 엣지와이즈는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 15일-9월 21일)

Large Cap

BMRN

BNTX

CHWY

KSPI

MUSA

RIVN

SMMT

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 서밋 테라퓨틱스(NASDAQ:SMMT)의 주식이 23.61% 하락했다. 이 회사는 새롭고 잠재적인 최초의 연구용 이중특이성 항체인 아이보네스시맙(ivonescimab)에 대한 데이터가 2024년 ESMO 연례 회의에서 발표되었다고 발표했다.

노보 노디스크, 츄이 및 페덱스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (9월 15일-9월 21일)

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma AS

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced that YORVIPATH&#xAE; (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour dosing period. It is the first and only medicine approved by the U.S. Food &amp; Drug Administration (FDA) for the treatment of hypoparathyroidism in adults.

Biotech

General

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
- Annualized height velocity was similar at Week 26 in once-weekly TransCon hGH-treated and daily somatropin-treated children
COPENHAGEN, Denmark, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced positive Week 26 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. to investigate the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; approved for pediatric growth hormone deficiency) compared to daily somatropin in prepubertal children with Turner syndrome.
New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 – one of three starting doses of TransCon hGH (0.24, 0.30, or 0.36 mg/kg/week) or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1.
<ul>
<li>On the primary endpoint of annualized height velocity and secondary endpoint of change from baseline in height SDS, children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose.
<ul>
<li>In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily somatropin.</li>
</ul>
</li>
</ul>

Ascendis Pharma Presents New InsiGHTS Trial Of TransCon hGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon hGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone Deficiency, Showed A Safety And Tolerability Profile Comparable To Daily Somatropin

Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced that the U.S. Food &amp; Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA&#xAE; for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025.

Ascendis Pharma Announces FDA Accepts Co's Supplemental Biologics License Application For TransCon hGH For The Treatment Of Adults With Growth Hormone Deficiency

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 4.86% since its last report. The company recently reported that it has 3.57 million shares sold short, which is 8.42% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733242521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 11.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Ascendis Pharma's Recent Short Interest

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and lowers the price target from $160 to $153.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Ascendis Pharma, Lowers Price Target to $153

Wedbush analyst Andreas Argyrides reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and maintains $181 price target.

Reiteration

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target

WIIM

Acendis Pharma shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $200 to $207.

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and lowers the price target from $190 to $180.

Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $180

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $170 price target.

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Buy and raises the price target from $200 to $207.

Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $207

Guidance

Ascendis Sees FY24 Operating Expenses ~€600M

Ascendis Pharma shares are trading lower. The company reported Q3 financial results.

Earnings

Ascendis Q3 2024 Revenue $€57.8M Vs €48M Prior

Ascendis Pharma's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NYSE">ASND</a>) short percent of float has risen 5.52% since its last report. The company recently reported that it has 3.41 million shares sold short, which is 8.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ascendis Pharma Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731604512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ascendis Pharma has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ascendis Pharma's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ascendis Pharma's peer group average for short interest as a percentage of float is 11.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(ASND) - Analyzing Ascendis Pharma's Short Interest

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ascendis Pharma to report an earnings per share (EPS) of $-1.66.
Ascendis Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.50, leading to a 11.27% drop in the share price on the subsequent day.
Here's a look at Ascendis Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.56</td>
<td></td>
<td>-2.15</td>
<td>-2.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.06</td>
<td>-2.5</td>
<td>-1.66</td>
<td>-3.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Ascendis Pharma Shares</h3>
Shares of Ascendis Pharma were trading at $127.67 as of November 12. Over the last 52-week period, shares are up 36.55%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ASND/earnings">To track all earnings releases for Ascendis Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Ascendis Pharma's Earnings Potential

Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NVO" target="_blank" rel="noreferrer noopener"> after market hours</a>. 
The stock is up 8.55% over the last year and 7.45% year-to-date.
Let&#8217;s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates.
<h2 class="wp-block-heading">Novo Nordisk Stock Chart Bearish Ahead Of Q3 Earnings</h2>
Novo Nordisk&#8217;s stock is showing strong bearish momentum, as its price of $108.76 sits below its five- 20- and 50-day exponential moving averages. This downward trend is accompanied by persistent selling pressure, suggesting potential for continued bearish movement.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM.png" alt="" class="wp-image-630249" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
With an eight-day simple moving average (SMA) of $111.67, a 20-day SMA of $115.16 and a 50-day SMA of $123.13 — all above the current price — technical indicators point to a bearish signal for NVO stock.
Additionally, the 200-day SMA at $128.29 further underscores the bearish outlook. 
The Moving Average Convergence Divergence (MACD) indicator at a negative 3.44 signals downside momentum, while a Relative Strength Index (RSI) of 25.06 indicates oversold conditions, hinting that NVO stock may face further declines without substantial support or a shift in buying interest.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/41685634/popular-weight-loss-drug-wegovy-shows-encouraging-results-in-liver-fibrosis-trial">Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial</a>
<h2 class="wp-block-heading">New Partnership For Longer-Acting GLP-1 Drugs</h2>
In a significant move to broaden its portfolio, Novo Nordisk has entered into <a href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug">a $285 million agreement</a> with Denmark-based Ascendis Pharma AS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>). This partnership grants Novo exclusive worldwide rights to Ascendis' TransCon technology, aiming to develop once-monthly GLP-1 receptor agonists for Type 2 diabetes and obesity — a step up from its weekly GLP-1 drugs.
The alliance also covers cardiovascular diseases, with Novo retaining the option to expand future metabolic treatments into additional therapeutic areas. Ascendis will lead early-stage development, while Novo handles the regulatory, manufacturing, and commercial phases.
The lead program in the partnership is a once-monthly GLP-1 drug, a potential game-changer for patients with metabolic disorders. Novo's recent clinical studies underscore the broader health impact of its GLP-1 treatments, showing reduced hospital admissions for heart disease in overweight patients, boosting investor confidence in the potential cardiovascular applications of the new drug.
<h2 class="wp-block-heading">Novo Nordisk Analysts See 46% Upside</h2>
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Novo Nordisk stock stands at a Buy with a price target of $123.86. The latest analyst ratings for Novo Nordisk stock from BMO Capital and Cantor Fitzgerald give an average price target of $158.67, suggesting 45.78% upside potential.
As Novo Nordisk readies to share its third-quarter performance, the dual narratives of bearish technicals and bullish analyst ratings, combined with a groundbreaking new partnership, make the upcoming earnings call a highly anticipated event.
Price Action: Novo Nordisk stock closed the trading day Monday at $109.72, down 1.98%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th">As Race To Best &#8216;Miracle&#8217; Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%</a></li>
</ul>
Image: Shutterstock

Health Care

Technicals

Previews

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

On Monday, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) granted Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41709477/ascendis-pharma-and-novo-nordisk-sign-collaboration-for-development-and-commercialization-of-trans" rel="noreferrer noopener">exclusive worldwide license</a>.
The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">Ascendis Pharma&#8217;s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year</a>
The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional provisions for cardiovascular diseases.
Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas.
The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.
Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales.
For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
Ascendis will conduct early development of TransCon product candidates in collaboration.
Novo Nordisk will be responsible for these early development costs, clinical development, regulatory, commercial manufacturing, and commercialization.
&#8220;The agreement with Novo Nordisk reflects our Vision 2030 to create value in additional large therapeutic areas outside endocrinology rare disease through collaborations with established global leaders,&#8221; said Jan Mikkelsen, Ascendis Pharma&#8217;s President and CEO.
&#8220;We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases,&#8221; said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.
The transaction is expected to close before the end of 2024.
Price Action: At the last check on Monday, ASND stock was up 1.91% at $127.67, and NVO stock was down 1.61% at $110.14.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41720697/totalenergies-bolsters-lng-presence-in-china-with-15-year-supply-deal-details" target="_blank" rel="noreferrer noopener">TotalEnergies Bolsters LNG Presence In China With 15-Year Supply Deal: Details</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Contracts

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) has outperformed the market over the past 15 years by 19.45% on an annualized basis producing an average annual return of 31.06%. Currently, Ascendis Pharma has a market capitalization of $7.49 billion. 
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a price of $125.28 for ASND at the time of writing.
<h3>Ascendis Pharma's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730739621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today

Ascendis Pharma (ASND) announced Week 26 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S....

Ascendis Pharma announces results from New InsiGHTS tril of TransCon hGH

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and As...

Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Ascendis Pharma (ASND – Research Report). The associated pri...

Buy Rating for Ascendis Pharma: Promising Phase 2 Trial Results and Upcoming US Launch Drive Positive Outlook

In a report released yesterday, David Lebowitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price target o...

Ascendis Pharma's Promising Growth Prospects: Buy Rating Backed by Positive Clinical Results and Expected Share Price Surge

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of $...

Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus

Harbor Health Care ETF Q3 2024 Commentary

The latest announcement is out from Ascendis Pharma ( ($ASND) ). Ascendis Pharma announced the expiration of the regulatory waiting period for its ...

Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk

Ascendis Pharma (ASND) announced that YORVIPATH is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parat...

Ascendis Pharma announces commercial availability of YORVIPATH in U.S.

Evercore ISI raised the firm's price target on Ascendis Pharma (ASND) to $220 from $205 and keeps an Outperform rating on the shares. The company i...

Ascendis Pharma price target raised to $220 from $205 at Evercore ISI

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Ascendis Pharma (ASND...

Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Ascendis Pharma (ASND)

DXCM

ICLR

LEGN

LRMR

MEDI

MRUS

NBIX

VERU

Press Releases

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Legal

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Ascendis Pharma Reports Third Quarter 2024 Financial Results

FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Comments

Ascendis Pharma

뉴스

에 대한 최신 뉴스 Ascendis Pharma (NASDAQ:ASND) 주식

월요일, 9월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌